FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107722406> ?p ?o ?g. }

• W2107722406 endingPage "90" @default.
• W2107722406 startingPage "86" @default.
• W2107722406 abstract "Interim results of a randomized, controlled, dose-finding study conducted in 24 dermatology centers on 217 patients with severe chronic plaque psoriasis (entry psoriasis area and severity index of at least 15) are presented. Patients were first treated with cyclosporine either 1.25 or 2.5 mg/kg/day (Sandimmune); in case of inadequate response the dosage was increased to a maximum of 5 mg/kg/day. Cyclosporine was given for 12 to 36 weeks. Treatment was classified as “successful” if the psoriasis area and severity index was reduced to 25% or less of the baseline value or below 8. At the end of the treatment period 18% of patients had improved their psoriasis area and severity index “successfully” with the initial dose of 1.25 mg/ kg/day. “Successful” improvement with the initial dose of 2.5 mg/kg/day was achieved in 56% of the cases. In the 1.25 mg group, 44 patients had to increase their dose to 2.5 mg/kg/ day and 31 patients to 5 mg/kg/day. In 29 patients whose dosages were started at 2.5 mg/ kg/day the dosage was subsequently increased to 5 mg/kg/day. Although 1.25 mg/kg/day proved to be effective in some cases, 2.5 mg/kg/day of cyclosporine is the optimal starting dose. Adverse events were observed in 10% of the patients taking 1.25 mg/kg/day, in 20% taking 2.5 mg/kg/day, and in 32% taking 5 mg/kg/day. The most common were gastrointestinal complaints, followed by the common cold and other viral infections. An increase of serum creatinine level above 130 Amol/L occurred in five patients who could continue therapy after reducing the dose. Among those patients taking 1.25, 2.5, or 5 mg/kg/ day of cyclosporine, 16.2%,17.1%, and 17.8%, respectively, were withdrawn from the study. The reasons were lack of efficacy (8.1% to 11%) and noncompliance (1.6% to 4.5%). A total of 1.6% to 3.2% of the patients discontinued the study because of adverse events. Interim results of a randomized, controlled, dose-finding study conducted in 24 dermatology centers on 217 patients with severe chronic plaque psoriasis (entry psoriasis area and severity index of at least 15) are presented. Patients were first treated with cyclosporine either 1.25 or 2.5 mg/kg/day (Sandimmune); in case of inadequate response the dosage was increased to a maximum of 5 mg/kg/day. Cyclosporine was given for 12 to 36 weeks. Treatment was classified as “successful” if the psoriasis area and severity index was reduced to 25% or less of the baseline value or below 8. At the end of the treatment period 18% of patients had improved their psoriasis area and severity index “successfully” with the initial dose of 1.25 mg/ kg/day. “Successful” improvement with the initial dose of 2.5 mg/kg/day was achieved in 56% of the cases. In the 1.25 mg group, 44 patients had to increase their dose to 2.5 mg/kg/ day and 31 patients to 5 mg/kg/day. In 29 patients whose dosages were started at 2.5 mg/ kg/day the dosage was subsequently increased to 5 mg/kg/day. Although 1.25 mg/kg/day proved to be effective in some cases, 2.5 mg/kg/day of cyclosporine is the optimal starting dose. Adverse events were observed in 10% of the patients taking 1.25 mg/kg/day, in 20% taking 2.5 mg/kg/day, and in 32% taking 5 mg/kg/day. The most common were gastrointestinal complaints, followed by the common cold and other viral infections. An increase of serum creatinine level above 130 Amol/L occurred in five patients who could continue therapy after reducing the dose. Among those patients taking 1.25, 2.5, or 5 mg/kg/ day of cyclosporine, 16.2%,17.1%, and 17.8%, respectively, were withdrawn from the study. The reasons were lack of efficacy (8.1% to 11%) and noncompliance (1.6% to 4.5%). A total of 1.6% to 3.2% of the patients discontinued the study because of adverse events." @default.
• W2107722406 created "2016-06-24" @default.
• W2107722406 creator A5006740586 @default.
• W2107722406 creator A5010643311 @default.
• W2107722406 creator A5023183786 @default.
• W2107722406 creator A5040894205 @default.
• W2107722406 creator A5043781155 @default.
• W2107722406 date "1992-01-01" @default.
• W2107722406 modified "2023-09-27" @default.
• W2107722406 title "Cyclosporine in psoriasis: A multicenter dose-finding study in severe plaque psoriasis" @default.
• W2107722406 cites W1967559083 @default.
• W2107722406 cites W1985676165 @default.
• W2107722406 cites W1987013299 @default.
• W2107722406 cites W2015994420 @default.
• W2107722406 cites W2019276276 @default.
• W2107722406 cites W2038026816 @default.
• W2107722406 cites W2074644577 @default.
• W2107722406 cites W2131493069 @default.
• W2107722406 cites W2416763681 @default.
• W2107722406 cites W2466527365 @default.
• W2107722406 doi "https://doi.org/10.1016/0190-9622(92)70012-5" @default.
• W2107722406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1732342" @default.
• W2107722406 hasPublicationYear "1992" @default.
• W2107722406 type Work @default.
• W2107722406 sameAs 2107722406 @default.
• W2107722406 citedByCount "91" @default.
• W2107722406 countsByYear W21077224062012 @default.
• W2107722406 countsByYear W21077224062013 @default.
• W2107722406 countsByYear W21077224062014 @default.
• W2107722406 countsByYear W21077224062015 @default.
• W2107722406 countsByYear W21077224062016 @default.
• W2107722406 countsByYear W21077224062017 @default.
• W2107722406 countsByYear W21077224062018 @default.
• W2107722406 countsByYear W21077224062019 @default.
• W2107722406 countsByYear W21077224062020 @default.
• W2107722406 countsByYear W21077224062021 @default.
• W2107722406 countsByYear W21077224062022 @default.
• W2107722406 countsByYear W21077224062023 @default.
• W2107722406 crossrefType "journal-article" @default.
• W2107722406 hasAuthorship W2107722406A5006740586 @default.
• W2107722406 hasAuthorship W2107722406A5010643311 @default.
• W2107722406 hasAuthorship W2107722406A5023183786 @default.
• W2107722406 hasAuthorship W2107722406A5040894205 @default.
• W2107722406 hasAuthorship W2107722406A5043781155 @default.
• W2107722406 hasConcept C126322002 @default.
• W2107722406 hasConcept C141071460 @default.
• W2107722406 hasConcept C16005928 @default.
• W2107722406 hasConcept C162156334 @default.
• W2107722406 hasConcept C168563851 @default.
• W2107722406 hasConcept C197934379 @default.
• W2107722406 hasConcept C2777011040 @default.
• W2107722406 hasConcept C2780564577 @default.
• W2107722406 hasConcept C30036603 @default.
• W2107722406 hasConcept C3020604521 @default.
• W2107722406 hasConcept C42219234 @default.
• W2107722406 hasConcept C71924100 @default.
• W2107722406 hasConcept C90924648 @default.
• W2107722406 hasConceptScore W2107722406C126322002 @default.
• W2107722406 hasConceptScore W2107722406C141071460 @default.
• W2107722406 hasConceptScore W2107722406C16005928 @default.
• W2107722406 hasConceptScore W2107722406C162156334 @default.
• W2107722406 hasConceptScore W2107722406C168563851 @default.
• W2107722406 hasConceptScore W2107722406C197934379 @default.
• W2107722406 hasConceptScore W2107722406C2777011040 @default.
• W2107722406 hasConceptScore W2107722406C2780564577 @default.
• W2107722406 hasConceptScore W2107722406C30036603 @default.
• W2107722406 hasConceptScore W2107722406C3020604521 @default.
• W2107722406 hasConceptScore W2107722406C42219234 @default.
• W2107722406 hasConceptScore W2107722406C71924100 @default.
• W2107722406 hasConceptScore W2107722406C90924648 @default.
• W2107722406 hasIssue "1" @default.
• W2107722406 hasLocation W21077224061 @default.
• W2107722406 hasLocation W21077224062 @default.
• W2107722406 hasOpenAccess W2107722406 @default.
• W2107722406 hasPrimaryLocation W21077224061 @default.
• W2107722406 hasRelatedWork W2028656318 @default.
• W2107722406 hasRelatedWork W2035287048 @default.
• W2107722406 hasRelatedWork W2060817629 @default.
• W2107722406 hasRelatedWork W2107722406 @default.
• W2107722406 hasRelatedWork W2152281374 @default.
• W2107722406 hasRelatedWork W2171689947 @default.
• W2107722406 hasRelatedWork W2898213950 @default.
• W2107722406 hasRelatedWork W4213143336 @default.
• W2107722406 hasRelatedWork W4255680485 @default.
• W2107722406 hasRelatedWork W4295255031 @default.
• W2107722406 hasVolume "26" @default.
• W2107722406 isParatext "false" @default.
• W2107722406 isRetracted "false" @default.
• W2107722406 magId "2107722406" @default.
• W2107722406 workType "article" @default.